Cognition Therapeutics, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Cognition Therapeutics, Inc. (CGTX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$4.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-26
- Cognition Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$4.93M.
- Cognition Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$7.13M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$4.93M 10-K · filed 2026-03-26 |
| 2024-12-31 | -$7.13M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |